In conclusion, we studied the prevalence of PIK3CA, RAS (KRAS, NRAS), and BRAF mutations in diverse tumor samples and identified a high frequency of coexisting PIK3CA and BRAF or RAS mutations. The gene discussed is BRAF; the disease is neoplasm.